Clinical Trial

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Study acronym: PPMI
Recruiting
View on ClinicalTrials.gov →
Summary
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Protocol Amendment History 79 amendments
This ClinicalTrials.gov record has been amended 79 times since 2020-07-15; most recent amendment 2026-07-24.
Trial Details
NCT Number NCT04477785
Lead Sponsor Michael J. Fox Foundation for Parkinson's Research
Collaborators: Institute for Neurodegenerative Disorders
Conditions Parkinson Disease
Enrollment 4,500 participants
Start Date 2020-07-01
Primary Completion 2033-12 (estimated)
Study Completion 2033-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-27